Full Press Release Details
Phase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress.
IDYA
Phase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Key Takeaway: Phase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma